Amyloid fibril is an important pharmaceutical target for diagnostic and therapeutic treatment
of neurodegenerative diseases. However, rational design of chemical compounds that …

Increasing evidence has suggested that formation and propagation of misfolded aggregates
of 42-residue human amyloid β (Aβ (1–42)), rather than of the more abundant Aβ (1–40) …

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder that
is characterized by amyloid β-protein deposition in senile plaques, neurofibrillary tangles …

Objective The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's
disease (AD) must be improved before widespread clinical use. This study aimed to …

In vitro, β-amyloid (Aβ) peptides form polymorphic fibrils, with molecular structures that
depend on growth conditions, plus various oligomeric and protofibrillar aggregates. Here …

Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular
pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development …

Neuropathologists assess vast brain areas to identify diverse and subtly-differentiated
morphologies. Standard semi-quantitative scoring approaches, however, are coarse …

There is an increasing role for biological markers (biomarkers) in the understanding and
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …

This review is concerned with the role of fibrillization of the amyloid β (Aβ)-peptide in
Alzheimer's disease (AD). The perspective is that of a physical chemist, and one aim is to …

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most
common cause of dementia with an estimated prevalence of 30 million people worldwide, a …